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Peripheral Ulcerative Keratitis Associated with Multiple Myeloma
Fig. 1. Perilimbal punched-in, thinning corneal epithelial defect, with 
infiltrates and undermined edges at 5 o’clock position of the right eye 
on presentation.          
Dear Editor,
Corneal involvement in multiple myeloma (MM) is rare. 
We would like to report a first case of peripheral ulcerative 
keratitis (PUK) associated with MM which improved on 
systemic corticosteroid treatment.
Clinical Picture
A 66-year-old lady with known MM presented with 
red painful right eye and reduced vision, with no ocular 
discharge. At the point of presentation, she had been 
diagnosed with MM for 2 months. She did not suffer 
from auto-immune diseases. Systemic examination was 
unremarkable. Blood test for rheumatoid factor, pANCA, 
cANCA, ANA and dsDNA were negative. Inflammatory 
markers were not elevated. Visual acuity was counting 
fingers (CF) in the affected eye. Ocular examination revealed 
an injected right eye with a punched-out and undermined 
perilimbal corneal epithelial defect and thinning at 5 o’clock 
position, with stromal infiltrates (Fig. 1). 
Treatment
Despite being on topical ocular antibiotics, it progressed 
to affect the limbal area. Corneal scrape for microscopy, 
staining and culture and sensitivity were negative, thus 
ruling out microbial cause of the keratitis. Fundoscopy 
was normal. Therefore an immune mediated mechanism 
was suspected and she was started on intravenous 
methylprednisolone (1 gram OD) for 2 days, followed by 
tapering dose of oral prednisolone (starting at 60 mg OD). 
Outcome
Two days later, the lesion improved with markedly reduced 
infiltrates and inflammation, and shrinking of the lesion (Fig. 
2). The vision improved to 6/18 on Snellen’s chart. This 
patient then completed her chemotherapy with remission 
of her MM, with no recurrence of any corneal pathology.
Fig. 2. The same corneal lesion in Fig. 1, 2 days post-systemic 
corticosteroid, showing markedly reduced infiltrates and 
inflammation, with the lesion size getting smaller.
 Discussion
Cornea involvement is uncommon in MM and involves 
crystalline and calcium deposits in the various layers.1 Our 
patient did not have any of these signs. She developed 
worsening PUK, whilst in between chemotherapy cycles 
for her MM, which was abated by systemic corticosteroid. 
It appeared that there was a temporal association between 
the development of PUK and MM which was considered 
to be active in between chemotherapy cycles. It is thought 
that she developed vasculitis secondary to MM, a rare 
association,2  leading to localised chemokine release, 
resulting in PUK3. Such association has not been previously 
reported. In conclusion, immune mediated PUK should be 
considered in MM and treated with systemic corticosteroid 
when infective causes of keratitis and autoimmune diseases3 
have been ruled out. In addition, MM should be considered 
when investigating patients for PUK. Our case highlights 
a first case of PUK associated with MM.
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